Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
	Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches (2020Q6)
The Resolution of Inflammation in Health and Disease (2018C6)
Injury, Inflammation and Fibrosis (2017C8)
Fibrosis: From Basic Mechanisms to Targeted Therapies (2016Q3)

Web Desc
Fibrosis: From Bench to Bedside Organizer(s): Jeremy S. Duffield, Steven R. Ledbetter and John P. Iredale Date: March 23 - 28, 2014 Location: Keystone Resort, Keystone, CO, USA Sponsored by Gilead Sciences, Inc., InterMune, Inc., MedImmune, Shire Human Genetic Therapies and Takeda Pharmaceutical Company Limited Summary of Meeting: Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests. Scholarship Deadline: November 20 2013 Discounted Abstract Deadline: November 20 2013 Abstract Deadline: December 18 2013 Discounted Registration Deadline: January 21 2014 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Promedior, Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Fibrosis: From Bench to Bedside

Organizer(s): Jeremy S. Duffield, Steven R. Ledbetter and John P. Iredale

Date: March 23 - 28, 2014
Location: Keystone Resort, Keystone, CO, USA

Sponsored by Gilead Sciences, Inc., InterMune, Inc., MedImmune, Shire Human Genetic Therapies and Takeda Pharmaceutical Company Limited

Summary of Meeting:

Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests.

Scholarship Deadline: November 20 2013

Discounted Abstract Deadline: November 20 2013

Abstract Deadline: December 18 2013

Discounted Registration Deadline: January 21 2014

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Promedior, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, March 23 \| 4:00PM - 8:00PM Arrival and Registration Room: Longs Peak Foyer
Sunday, March 23 \| 6:00PM - 8:00PM Welcome Mixer Room: Longs Peak Foyer
Monday, March 24 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Monday, March 24 \| 8:00AM - 8:15AM Introduction Room: Longs/Grays Peaks Speaker 1 of 1 Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Monday, March 24 \| 8:15AM - 9:15AM Keynote Address Room: Longs/Grays Peaks Speaker 1 of 3 * Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Monday, March 24 \| 8:15AM - 9:15AM Keynote Address Room: Longs/Grays Peaks Speaker 2 of 3 * Steven R. Ledbetter, Genzyme Corporation, USA
Monday, March 24 \| 8:15AM - 9:15AM Keynote Address Room: Longs/Grays Peaks Speaker 3 of 3 Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, Blade Therapeutics, USA Insights Regarding the Pathogenesis and Treatment of Scleroderma
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 1 of 8 * Erwin P. Böttinger, Hasso-Plattner-Institut für Digital Engineering GmbH, Germany
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 2 of 8 * Steven R. Ledbetter, Genzyme Corporation, USA
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 3 of 8 Judith Campisi, Buck Institute for Research on Aging, USA The Role of Cellular Senescence in Inflammation and Fibrosis
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 4 of 8 Dean Sheppard, University of California, San Francisco, USA Fibroblast alphav Integrins as Therapeutic Targets in Tissue Fibrosis
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 5 of 8 John P. Iredale, University of Bristol, UK Macrophages and Resolution of Liver Fibrosis
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 6 of 8 David Lagares, Massachusetts General Hospital, USA Short Talk: “Fibronucleation” and Stiffness Gradients Drive Tissue Fibrosis by Promoting Fibroblast Recruitment and Activation through Cell “Durotaxis”
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 7 of 8 Massimiliano Mellone, University of Southampton, UK Short Talk: Fibroblast to Myofibroblast Differentiation in Fibrosis and Tumor Microenvironment: Role of DNA Damage Response (DDR) Pathway
Monday, March 24 \| 9:15AM - 12:00PM Senescence, Cell Stress and the Fibrogenic Response Room: Longs/Grays Peaks Speaker 8 of 8 Neetu Razdan, Rutgers University, USA Short Talk: Telomere Dysfunction Is a Mediator of Myofibroblast Transdifferentiation
Monday, March 24 \| 9:55AM - 10:15AM Coffee Break Room: Longs Peak Foyer
Monday, March 24 \| 12:00PM - 1:00PM Poster Setup Room: Shavano/Torreys
Monday, March 24 \| 12:00PM - 5:00PM On Own for Lunch and Recreation
Monday, March 24 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Monday, March 24 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 1 of 7 * Thomas A. Wynn, Pfizer, USA
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 2 of 7 * John Varga, Feinberg School of Medicine, USA
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 3 of 7 Rik Derynck, University of California, San Francisco, USA Control of Epithelial-Mesenchymal Transition by TGF-beta Receptor Presentation
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 4 of 7 Erwin P. Böttinger, Hasso-Plattner-Institut für Digital Engineering GmbH, Germany Mitochondrial Dysfunction and Renal Fibrogenesis
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 5 of 7 Nelson Chau, LogicBio Therapeutics, USA Oligonucleotide-Mediated Antagonism of Dysregulated MicroRNAs Represents a Novel Therapeutic Strategy for Treatment of Fibrosis
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 6 of 7 Benjamin Korman, Northwestern University, USA Short Talk: Adipocyte-Specific Ablation of PPAR-gamma Co-Repressor NCoR Modulates Metabolism and Attenuates Experimental Skin Fibrosis
Monday, March 24 \| 5:00PM - 7:15PM Metabolic Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 7 of 7 Monique Bernard, University of Montreal Hospital Centre - Research Centre, CRCHUM, Canada Short Talk: mTORC2 Links Autophagy and Myofibroblast Differentiation
Monday, March 24 \| 7:15PM - 8:15PM Social Hour with Lite Bites Room: Shavano/Torreys
Monday, March 24 \| 7:30PM - 10:00PM Poster Session 1: 1A Fate Mapping Studies 1B Metabolic /Stress/Senescence Pathways 1C Scleroderma/Systemic Sclerosis 1D New Insights from Screens 1E Reprogramming/Epigenetics 1F MicroRNA 1G Perivasculature Room: Shavano/Torreys Speaker 1 of 3 * David A. Brenner, University of California, San Diego, USA
Monday, March 24 \| 7:30PM - 10:00PM Poster Session 1: 1A Fate Mapping Studies 1B Metabolic /Stress/Senescence Pathways 1C Scleroderma/Systemic Sclerosis 1D New Insights from Screens 1E Reprogramming/Epigenetics 1F MicroRNA 1G Perivasculature Room: Shavano/Torreys Speaker 2 of 3 * Jelena Mann, Newcastle University, UK
Monday, March 24 \| 7:30PM - 10:00PM Poster Session 1: 1A Fate Mapping Studies 1B Metabolic /Stress/Senescence Pathways 1C Scleroderma/Systemic Sclerosis 1D New Insights from Screens 1E Reprogramming/Epigenetics 1F MicroRNA 1G Perivasculature Room: Shavano/Torreys Speaker 3 of 3 * Boris Hinz, University of Toronto, Canada
Tuesday, March 25 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 1 of 8 * Andrew M. Tager, Massachusetts General Hospital, USA
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 2 of 8 Jeremy S. Duffield, Vertex Pharmaceuticals, USA Mechanisms of Perivascular Cell Activation in Disease
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 3 of 8 Lucie Peduto, Institut Pasteur, France The Fate and Function of ADAM12(+) Perivascular Cells in Injury and Fibrosis
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 4 of 8 Christian Göritz, Karolinska Institutet, Sweden The Role of Pericytes in Central Nervous System Scarring and Fibrosis
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 5 of 8 Jonathan M. Graff, University of Texas Southwestern Medical Center, USA Adipose Stem Cells: Give me a Pill and not a Treadmill
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 6 of 8 Ingmar Mederacke, Columbia University, USA Short Talk: Fate Tracing Reveals Hepatic Stellate Cells as Main Contributors to the Myofibroblast Pool in Toxic, Biliary and Fatty Liver Disease
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 7 of 8 Tien Peng, University of Pennsylvania, USA Short Talk: Hedgehog Regulates Fibroblast Proliferation during Normal Tissue Homeostasis and Fibrotic Repair
Tuesday, March 25 \| 8:00AM - 11:45AM Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis Room: Longs/Grays Peaks Speaker 8 of 8 * Andrew Leask, University of Saskatoon, Canada Short Talk: Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis
Tuesday, March 25 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Tuesday, March 25 \| 11:45AM - 1:00PM Poster Setup Room: Shavano/Torreys
Tuesday, March 25 \| 11:45AM - 2:30PM On Own for Lunch and Recreation
Tuesday, March 25 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 1 of 9 * Heather A. Arnett, NuMedii, Inc., USA
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 2 of 9 * Kamran Atabai, University of California, San Francisco, USA
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 3 of 9 Martin L. Decaris, Pliant Therapeutics, USA Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 4 of 9 Terrie-Anne Cock, Pharmaxis, Australia Inhibition of TGF-beta Signaling and LOXL2: Pharmaxis’ Dual Small Molecule Approach to Treat Fibrosis
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 5 of 9 Ming-Hui Fan, University of Pittsburgh, USA Fibroblast Activation Protein (FAP), An Endogenous Regulator of Fibrosis, Participates in Collagen Catabolism
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 6 of 9 Thomas H. Barker, Georgia Institute of Technology, USA A CD90/Fyn/alphavbeta3 Integrin Mechanosignaling Axis Modulates ECM Rigidity Sensing in Lung Fibrosis
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 7 of 9 Franco Klingberg, University of Toronto, Canada Organized Is More Efficient: Pre-Stress in the ECM Enhances Activation of Latent TGF-beta1 by Myofibroblast Contraction
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 8 of 9 Peter D. Mariner, University of Colorado, USA Dynamic Hydrogel Platform for Studying the Effects of Environmental Stiffness on Myofibroblast Activation
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea ? Room: Longs/Grays Peaks Speaker 9 of 9 Nathan Sandbo, University of Wisconsin, USA Myofibroblasts Exhibit Elevated Fibronectin Assembly that Is Intrinsic to its Contractile Phenotype
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 1 of 9 * Harry (Hal) C. Dietz, Johns Hopkins University School of Medicine, Blade Therapeutics, USA
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 2 of 9 * Tatiana Kisseleva, University of California, San Diego, USA
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 3 of 9 Sergei P. Atamas, University of Maryland School of Medicine, USA Deciphering Mechanisms of IL-33-Driven Fibrosis
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 4 of 9 Christian Beyer, University of Erlangen-Nuremberg, Germany The Soluble Guanylate Cyclase (sGC) Inhibits Fibrosis by Interfering with Non-Canonical TGFbeta-Signaling
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 5 of 9 Michael P. Czubryt, University of Manitoba, Canada Regulation of Myocardial Fibrogenesis and Fibroblast Phenotype by Scleraxis
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 6 of 9 Emily Hamburg, Case Western Reserve University, USA Cell Autonomous Mechanisms of Fibrosis Due to Elevated beta-Catenin Activity in Dermal Fibroblasts
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 7 of 9 Alison E. John, University of Nottingham, UK Alveolar TGF-beta Activation and Lung Homeostasis Is Regulated by Epithelial Gq/G11 Signaling
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 8 of 9 Katherine M. Martin, University of Manchester, UK Integrin Beta1 Regulates Hepatic Stellate Cell Activation
Tuesday, March 25 \| 2:30PM - 4:30PM Workshop 1B: How Best to Regulate Myofibroblast Activation Room: Quandary Peak Speaker 9 of 9 Saimir Luli, Newcastle University, UK A Novel Liposomal Technology to Selectively Target Hepatic Myofibroblasts
Tuesday, March 25 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 1 of 7 * John P. Iredale, University of Bristol, UK
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 2 of 7 * Timothy Radstake, University Medical Center Utrecht, Netherlands
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 3 of 7 Paul Kubes, University of Calgary, Canada Intravascular Immunity in the Development and Resolution of Sterile Injury
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 4 of 7 Thomas A. Wynn, Pfizer, USA Macrophage Subsets in Type-2-Dependent Fibrosis
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 5 of 7 Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA Autophagy Fuels Mesenchymal Cell Fibrogenesis in Liver and Other Tissues
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 6 of 7 Brigid M. O'Flaherty, Emory University, USA Short Talk: Evaluating the Role of MHV68 M1 Induced Vbeta4+CD8+ T Cell Expansion in Development of Pulmonary Fibrosis
Tuesday, March 25 \| 5:00PM - 7:15PM Innate and Adaptive Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 7 of 7 Christian Stockmann, University of Zurich, Switzerland Short Talk: Sinusoidal Remodeling by Myeloid Cell-Derived VEGF Is Required for the Resolution of Liver Fibrosis
Tuesday, March 25 \| 7:15PM - 8:15PM Social Hour with Lite Bites Room: Shavano/Torreys
Tuesday, March 25 \| 7:30PM - 10:00PM Poster Session 2: 2A Infectious Mechanisms 2B New Targ ets 2C Innate/Adaptive Immunity 2D Underrepresented Organs/Diseases 2E Repair/Regeneration Room: Shavano/Torreys Speaker 1 of 3 * Lynn M. Schnapp, University of Wisconsin-Madison, USA
Tuesday, March 25 \| 7:30PM - 10:00PM Poster Session 2: 2A Infectious Mechanisms 2B New Targ ets 2C Innate/Adaptive Immunity 2D Underrepresented Organs/Diseases 2E Repair/Regeneration Room: Shavano/Torreys Speaker 2 of 3 * Paul Kubes, University of Calgary, Canada
Tuesday, March 25 \| 7:30PM - 10:00PM Poster Session 2: 2A Infectious Mechanisms 2B New Targ ets 2C Innate/Adaptive Immunity 2D Underrepresented Organs/Diseases 2E Repair/Regeneration Room: Shavano/Torreys Speaker 3 of 3 * Paul W. Noble, Cedars-Sinai Medical Center, USA
Wednesday, March 26 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 1 of 11 * Dean Sheppard, University of California, San Francisco, USA
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 2 of 11 * Mark L. Lupher, Jr., Muregen, LLC, USA
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 3 of 11 Paul W. Noble, Cedars-Sinai Medical Center, USA Update on Clinical Trials in Idiopathic Pulmonary Fibrosis
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 4 of 11 Naftali Kaminski, Yale University School of Medicine, USA MicroRNAs in Lung Fibrosis
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 5 of 11 Elizabeth G. Trehu, Jounce Therapeutics, USA and
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 6 of 11 Bernt van den Blink, Erasmus MC, Netherlands PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 7 of 11 Andrew M. Tager, Massachusetts General Hospital, USA Lysophosphatidic Acid (LPA)-LPA1 Signaling in Fibrogenesis
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 8 of 11 Jeffrey R. Crosby, Ionis Pharmaceuticals, Inc., USA Short Talk: Inhaled Antisense Oligonucleotides for the Treatment of Pulmonary Fibrosis: The Role of Osteopontin in Mouse Models of Disease
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 9 of 11 Cédric Szyndralewiez, Genkyotex, Switzerland Short Talk: The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 10 of 11 Timothy Radstake, University Medical Center Utrecht, Netherlands Short Talk: The Chemokine CXCL4 Is a Novel biomarker in Systemic Sclerosis Linking Inflammation, Endothelial Dysfunction and Fibrosis
Wednesday, March 26 \| 8:00AM - 11:45AM Established and Promising Therapies Entering Clinical Develo pment Room: Longs/Grays Peaks Speaker 11 of 11 Mushriq Al-Jazrawe, University of Toronto, Canada Short Talk: Preventing Fibrosis by Targeting beta-Catenin: A Preclinical Study of Topical Nefopam
Wednesday, March 26 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Wednesday, March 26 \| 11:45AM - 1:00PM Poster Setup Room: Shavano/Torreys
Wednesday, March 26 \| 11:45AM - 5:00PM On Own for Lunch and Recreation
Wednesday, March 26 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano/Torreys
Wednesday, March 26 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 1 of 7 * Paul W. Noble, Cedars-Sinai Medical Center, USA
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 2 of 7 * Victoria Smith, Gilead Sciences, USA
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 3 of 7 Heather A. Arnett, NuMedii, Inc., USA Identifying Novel Myofibroblast Pathways in IPF Lungs
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 4 of 7 Robert Lafyatis, University of Pittsburgh Medical Center, USA Anti-TGF-beta/Fresolimumab Inhibition of Skin Fibrosis and TGF-beta-Regulated Biomarker Gene Expression in Patients with Systemic Sclerosis
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 5 of 7 Greg R. Dressler, University of Michigan, USA Novel TGF-beta Superfamily Regulators in Renal Fibrosis
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 6 of 7 James P. Pritchett, University of Manchester, UK Short Talk: A Role for Mechano-Transduction via Yap/Taz in Hepatic Stellate Cell Activation
Wednesday, March 26 \| 5:00PM - 7:15PM Promising New Pathways in Fibrogenesis Room: Longs/Grays Peaks Speaker 7 of 7 Cristi L. Galindo, Vanderbilt University, USA Short Talk: Neuregulin Inhibits Cardiac Fibrosis and Mediates Anti-Fibrotic Signaling in Cardiac Fibroblasts
Wednesday, March 26 \| 7:15PM - 8:15PM Social Hour with Lite Bites Room: Shavano/Torreys
Wednesday, March 26 \| 7:30PM - 10:00PM Poster Session 3: 3A Clinical Trials 3B Biomarkers/Mon itoring/Devices 3C New Models 3D Signaling 3E Matrix Signaling to Cells Room: Shavano/Torreys Speaker 1 of 3 * Bruno Péault, University of California, Los Angeles, USA
Wednesday, March 26 \| 7:30PM - 10:00PM Poster Session 3: 3A Clinical Trials 3B Biomarkers/Mon itoring/Devices 3C New Models 3D Signaling 3E Matrix Signaling to Cells Room: Shavano/Torreys Speaker 2 of 3 * Stuart J. Forbes, University of Edinburgh, UK
Wednesday, March 26 \| 7:30PM - 10:00PM Poster Session 3: 3A Clinical Trials 3B Biomarkers/Mon itoring/Devices 3C New Models 3D Signaling 3E Matrix Signaling to Cells Room: Shavano/Torreys Speaker 3 of 3 * Andrew M. Tager, Massachusetts General Hospital, USA
Thursday, March 27 \| 7:00AM - 8:00AM Breakfast Room: Shavano/Torreys
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 1 of 10 * Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 2 of 10 * Tien Peng, University of Pennsylvania, USA
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 3 of 10 Bruno Péault, University of California, Los Angeles, USA Role of Vascular Pericytes in Normal and Pathologic Tissue Regeneration
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 4 of 10 Gabrielle Kardon, University of Utah, USA Interactions between Muscle Stem Cells, Fibroblasts and Macrophages Are Critical for Muscle Regeneration
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 5 of 10 Stuart J. Forbes, University of Edinburgh, UK Liver Regeneration
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 6 of 10 Michelle D. Tallquist, University of Hawaii, USA Cardiac Resident Mesenchymal Cells in Organogensis and Fibrosis
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 7 of 10 Dario R. Lemos, University of British Columbia, Canada Short Talk: The Innate Immune Response Modulates Fibrosis during Skeletal Muscle Regeneration via TNF-alpha/TGF-beta Signaling on Mesenchymal Multipotent Cells
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 8 of 10 Laura Johnson, University of Michigan, USA Short Talk: Intestinal Organoids: A Model of Intestinal Fibrosis
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 9 of 10 Wilder Scott, University of British Columbia, Canada Short Talk: Analysis of Mesenchymal Stromal Cell Fate in Tissue Regeneration
Thursday, March 27 \| 8:00AM - 11:45AM Resolution of Fibrosis and Pathways of Repair and Regenerati on Room: Longs/Grays Peaks Speaker 10 of 10 Norihiko Takeda, University of Tokyo, Japan Short Talk: Roles of Macrophages Hypoxia Signaling in Cardiac Fibrosis
Thursday, March 27 \| 9:20AM - 9:40AM Coffee Break Room: Longs Peak Foyer
Thursday, March 27 \| 11:45AM - 2:30PM On Own for Lunch and Recreation
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 1 of 10 * Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 2 of 10 Edford Sinkala, University Teaching Hospital, Zambia High Concentration of Fibrotic and Inflammatory Markers among Patients with Schistosomal Liver Diseases
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 3 of 10 Scott M. Turner, Pliant Therapeutics, USA Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 4 of 10 John A. Baugh, University College Dublin, Ireland Serum Amyloid P-Component: A Novel Biomarker and Potential Treatment for Left Ventricular Remodelling and Heart Failure
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 5 of 10 Thomas H. Barker, Georgia Institute of Technology, USA A New Modality for Imaging Fibrosis - Detection of an Extracellular Integrin “Switch” A Conformation Specific Antibody against Fibronectin for Imaging of Fibrosis
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 6 of 10 Florin L. Craciun, Brigham & Women's Hospital/ Harvard Medical School, USA Discovery of 12 New Candidate Biomarkers for Chronic Kidney Disease: From Mouse Models to Human Patients
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 7 of 10 Claire Emson, Genentech, Inc., USA Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 8 of 10 Jose D. Herazo-Maya, Yale University, USA A 52 Peripheral Blood Gene Signature Predicts Poor Outcome and Disease Progression in Idiopathic Pulmonary Fibrosis
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 9 of 10 Mette Juul Nielsen, Nordic Bioscience, Denmark Serological Markers of Extracellular Matrix Remodeling Enables Early Diagnosis and Predicts Fibrosis Progression of Chronic Hepatitis C
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices Room: Quandary Peak Speaker 10 of 10 Karl Kossen, Blade Therapeutics, USA Plasma MMP-7 Predicts Mortality in Idiopathic Pulmonary Fibrosis
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 1 of 9 * Linda C. Burkly, Biogen, Inc., USA
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 2 of 9 * Stuart J. Forbes, University of Edinburgh, UK
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 3 of 9 David Zhang, Mount Sinai School of Medicine, USA A Genomics Strategy Highlights Hand2 Regulation in Hepatic Stellate Cell Activation
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 4 of 9 Kamran Atabai, University of California, San Francisco, USA Functional Genomic Screen Identifies Novel Mediators of Collagen Uptake and Turnover
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 5 of 9 Xavier Espanel, NovAliX Belgique, France Development and Automation of a Fibrotic Phenotypic Screening Using a High Content Screening Approach
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 6 of 9 David W. Griggs, St. Louis University, USA Preclinical Development of Multi-Functional Integrin Antagonists for Treatment of Organ Fibrosis
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 7 of 9 John B. Nicholas, InterMune, Inc., USA Phenotypic Screening for Inhibitors of Fibroblast to Myofibroblast Transition (FMT)
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 8 of 9 Kevin K. Kim, University of Michigan, USA Overexpression of Id2 Transcription Factor Promotes Alveolar Epithelial Cell Proliferation and Attenuates Belomycin-Induced Pulmonary Fibrosis
Thursday, March 27 \| 2:30PM - 4:30PM Workshop 2B: New Pathways/Drugs from SCREENS Room: Longs/Grays Peaks Speaker 9 of 9 Branko Stefanovic, Florida State University, USA Discovery and Validation of a Potent Antifibrotic Drug with Unique Mechanism of Action
Thursday, March 27 \| 4:30PM - 5:00PM Coffee Available Room: Longs Peak Foyer
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 1 of 6 * Michelle D. Tallquist, University of Hawaii, USA
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 2 of 6 * Naftali Kaminski, Yale University School of Medicine, USA
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 3 of 6 David A. Brenner, University of California, San Diego, USA Myofibroblast Inactivation in the Resolution of Fibrosis
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 4 of 6 Jelena Mann, Newcastle University, UK Epigenetics in Myofibroblast Reprogramming
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 5 of 6 Boris Hinz, University of Toronto, Canada The Effect of the Mechanical Environment on Myofibroblast Development and Persistence
Thursday, March 27 \| 5:00PM - 7:00PM Myofibroblast Reprogramming Room: Longs/Grays Peaks Speaker 6 of 6 Eleni Stylianou, Lerner Research Institute, Cleveland Clinic, USA Short Talk: Defining the Fibrotic DNA Methylome in Crohn’s Disease
Thursday, March 27 \| 7:00PM - 7:10PM Concluding Remarks Speaker 1 of 1 Jeremy S. Duffield, Vertex Pharmaceuticals, USA
Thursday, March 27 \| 7:10PM - 8:10PM Social Hour with Lite Bites Room: Shavano/Torreys
Thursday, March 27 \| 8:00PM - 11:00PM Entertainment Room: Shavano/Torreys
Thursday, March 27 \| 8:00PM - 11:00PM Cash Bar Room: Shavano/Torreys
Friday, March 28 \| 10:25AM - 10:25AM Departure *Session Chair.